National Health Service

Global Nonwoven Disposable Gloves Market Report 2023: Sector is Expected to Reach $1.72 Billion by 2030 at a CAGR of 8.7% - ResearchAndMarkets.com

Retrieved on: 
Monday, May 22, 2023
Medical Supplies, Health, Fungal infection, Infection, Occupational safety and health, National Health Service, United Nations, Hospital, Ageing, Element, USD, Houston, Incidence, Nursing, Patient, United, Risk, Blood, Water, Conditional sentence, Growth, Fluid mechanics, NHS, Skin, Safety, Thermoplastic, Pharmaceutical industry, Leather, Agriculture

The global nonwoven disposable gloves market size is anticipated to reach USD 1.72 billion by 2030, registering a CAGR of 8.7% from 2023 to 2030.

Key Points: 
  • The global nonwoven disposable gloves market size is anticipated to reach USD 1.72 billion by 2030, registering a CAGR of 8.7% from 2023 to 2030.
  • Pre-soaped and non-soaped, soft nonwoven disposable gloves are primarily used in medical applications for the professional cleaning of body parts.
  • Non-soaped disposable gloves emerged as the leading segment for their applications in household commercial cleaning and spa applications.
  • The main drivers of increased demand for nonwoven disposable gloves are the high incidence of chronic diseases and hospitalization rates.

Freeline Granted ILAP Designation in United Kingdom by MHRA for FLT201, an Investigational Gene Therapy for the Treatment of Gaucher Disease

Retrieved on: 
Monday, May 22, 2023
Gaucher's disease, National Health Service, Health care, Healthcare Improvement Scotland, Wales, Marketing, MD, Patient, National Institute for Health and Care Excellence, Innovation, NHS, MAA, Therapy, NICE, SMC, MHRA, Disease, Pharmaceutical industry, Gaucher

Medicines and Healthcare products Regulatory Agency (MHRA).

Key Points: 
  • Medicines and Healthcare products Regulatory Agency (MHRA).
  • “We believe FLT201 has life-changing potential for people with Gaucher disease type 1, the most common type of the disease,” said Pamela Foulds, MD, Chief Medical Officer of Freeline.
  • Existing therapies come with a heavy life-long treatment burden, and even with treatment, many patients continue to experience serious symptoms.
  • We believe that FLT201 may improve outcomes for patients with a one-time gene therapy.

One of UK’s Largest National Health Service Providers Selects Riverbed to Enhance the Digital Experience for Clinicians to Help Deliver Better Healthcare to the Community

Retrieved on: 
Thursday, May 18, 2023
Data Management, Apps, Applications, Technology, Software, Networks, Internet, Kent Community Health NHS Foundation Trust, Life, National Health Service, Carbon, Kent, Patient, Risk, Investment, Patient safety, EPR, Ageing, NHS, Health, DEM, Pharmaceutical industry, Nursing, Online shopping, Stream bed

Riverbed®, the leader in unified observability, today announced that Kent Community Health NHS Foundation Trust (KCHFT) – one of the largest National Health Service (NHS) community health providers in the UK – has deployed Alluvio™ Aternity Digital Experience Management (DEM) to support its digital experience strategy.

Key Points: 
  • Riverbed®, the leader in unified observability, today announced that Kent Community Health NHS Foundation Trust (KCHFT) – one of the largest National Health Service (NHS) community health providers in the UK – has deployed Alluvio™ Aternity Digital Experience Management (DEM) to support its digital experience strategy.
  • As a result, it took time to determine the root cause of performance problems affecting staff and patient journeys.
  • After careful evaluation, KCHFT chose to purchase the Alluvio Aternity Digital Experience Management (DEM) solution from Riverbed, deploying 6,200 licenses.
  • To achieve this, clinicians require a seamless end-user experience – using technology to enhance patient safety and drive efficiency into pathways.

Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus

Retrieved on: 
Thursday, May 18, 2023
New England, National Health Service, Barts Health NHS Trust, Chronic kidney disease, Medicine, Health care, Quality of life, Medication, CSL Vifor, Hemodialysis, Medicines and Healthcare products Regulatory Agency, Patient, Itch, Therapy, CKD, NICE, MHRA, National Institute for Health and Care Excellence, Nursing, Pharmaceutical industry

ST. GALLEN, Switzerland and STAMFORD, Conn., May 18, 2023 /PRNewswire/ -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that England's National Institute for Health and Care Excellence (NICE) has recommended Kapruvia® for the treatment of moderate-to-severe CKD-associated pruritus in adult patients on haemodialysis. The decision follows authorisation from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) in April 2022.

Key Points: 
  • The decision follows authorisation from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) in April 2022.
  • "The recommendation of Kapruvia® by NICE is a key step on our journey to bring this breakthrough treatment to in-centre haemodialysis patients living with moderate-to-severe CKD-associated pruritus in the UK," said Fabio Dorigotti, Head Global Medical Affairs of CSL Vifor.
  • "We look forward to continue working with the National Health Service to ensure access to this important medicine for patients as quickly as possible."
  • "Together with VFMCRP, we are committed to bringing our first-of-its kind therapy to providers and patients around the world to help change the way pruritus is managed."

Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus

Retrieved on: 
Thursday, May 18, 2023
New England, National Health Service, Barts Health NHS Trust, Chronic kidney disease, Medicine, Health care, Quality of life, Medication, CSL Vifor, Hemodialysis, Medicines and Healthcare products Regulatory Agency, Patient, Itch, Therapy, CKD, NICE, MHRA, National Institute for Health and Care Excellence, Nursing, Pharmaceutical industry

ST. GALLEN, Switzerland and STAMFORD, Conn., May 18, 2023 /PRNewswire/ -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that England's National Institute for Health and Care Excellence (NICE) has recommended Kapruvia® for the treatment of moderate-to-severe CKD-associated pruritus in adult patients on haemodialysis. The decision follows authorisation from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) in April 2022.

Key Points: 
  • The decision follows authorisation from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) in April 2022.
  • "The recommendation of Kapruvia® by NICE is a key step on our journey to bring this breakthrough treatment to in-centre haemodialysis patients living with moderate-to-severe CKD-associated pruritus in the UK," said Fabio Dorigotti, Head Global Medical Affairs of CSL Vifor.
  • "We look forward to continue working with the National Health Service to ensure access to this important medicine for patients as quickly as possible."
  • "Together with VFMCRP, we are committed to bringing our first-of-its kind therapy to providers and patients around the world to help change the way pruritus is managed."

Kapruvia® (difelikefalin) recommended by England’s NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus

Retrieved on: 
Thursday, May 18, 2023
New England, National Health Service, Barts Health NHS Trust, Medicine, Health care, Quality of life, CSL Vifor, Hemodialysis, Patient, Therapy, CKD, NICE, MHRA, Pharmaceutical industry

ST. GALLEN, Switzerland and STAMFORD, Conn., May 18, 2023 (GLOBE NEWSWIRE) -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that England’s National Institute for Health and Care Excellence (NICE) has recommended Kapruvia® for the treatment of moderate-to-severe CKD-associated pruritus in adult patients on haemodialysis.

Key Points: 
  • ST. GALLEN, Switzerland and STAMFORD, Conn., May 18, 2023 (GLOBE NEWSWIRE) -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that England’s National Institute for Health and Care Excellence (NICE) has recommended Kapruvia® for the treatment of moderate-to-severe CKD-associated pruritus in adult patients on haemodialysis.
  • The decision follows authorisation from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in April 2022.
  • “The recommendation of Kapruvia® by NICE is a key step on our journey to bring this breakthrough treatment to in-centre haemodialysis patients living with moderate-to-severe CKD-associated pruritus in the UK,” said Fabio Dorigotti, Head Global Medical Affairs of CSL Vifor.
  • “We now have an option to help reduce the burden of CKD-related itch.”
    MHRA approval and the NICE recommendation were supported by positive data from two pivotal phase-III trials – KALM-1, conducted in the U.S. (New England Journal of Medicine 2020; 382:222-232), and the global KALM-2, as well as supportive data from an additional 32 clinical studies.

Smartphone psychotherapy trial with MGH reveals multiple patterns of effective engagement in mental health treatment

Retrieved on: 
Thursday, May 11, 2023
Learning, National Health Service, Doctor of Psychology, OCD, Psychology, Cognitive behavioral therapy, Research, Sampler, Doctor of Philosophy, CBT, Assistant, Harvard Medical School, Internet, Development, BDD, Patient, Mass, Perspective, Mass General Brigham, CORD, Hospital, Digital, NHS, Massachusetts General Hospital, News, NICE, Body dysmorphic disorder, Mobile phone, Medical device, Nursing

BOSTON, May 11, 2023 /PRNewswire-PRWeb/ -- 

Key Points: 
  • While numerous studies support the use of CBT for BDD, many patients are unable to find providers with expertise in this therapy modality or cannot afford treatment.
  • Extended analysis of the 12-week randomized waitlist-controlled trial results showed improvement in BDD severity across three types of users who exhibited different patterns of engagement with the app, namely samplers, deep users and light users.
  • Deep users engaged with the app less overall, but when they did log in, engaged more deeply for a longer time.
  • Deep users experienced marginally higher levels of improvement than light users, but the results suggest varying levels of engagement can be efficacious.

Cambridge University Hospitals Expands Virtual Care Program with Masimo W1™

Retrieved on: 
Monday, May 8, 2023
Medical Devices, Hospitals, Health Technology, Telemedicine, Virtual Medicine, Health Insurance, Biometrics, Biotechnology, Managed Care, General Health, Health, National Health Service, Eye, Cambridge University Hospitals NHS Foundation Trust, ECG, Multimedia, MASI, Patient, Virtual Hospital, History of the National Health Service (England), NHS, FDA, Nursing, Hospital, Masimo

Masimo (NASDAQ: MASI) today announced that Cambridge University Hospitals NHS Foundation Trust, U.K. is adopting the Masimo W1™ advanced health tracking watch for use in its telehealth and telemedicine programs.

Key Points: 
  • Masimo (NASDAQ: MASI) today announced that Cambridge University Hospitals NHS Foundation Trust, U.K. is adopting the Masimo W1™ advanced health tracking watch for use in its telehealth and telemedicine programs.
  • We are excited for Cambridge clinicians and patients.”
    Cambridge University Hospitals NHS Foundation Trust launched its virtual ward program in 2022, as part of a National Health Service (NHS) England telehealth initiative designed to promote earlier patient discharge to the home.
  • Dr. Iain Goodhart, Clinical Director of the Virtual Hospital Program at Cambridge University Hospitals NHS Foundation Trust, commented, “Masimo W1 will help us expand our Virtual Hospital program by offering continuous monitoring of oxygen saturation and pulse rate, as well as ECG spot-checking, in a comfortable, easy to use watch.
  • We’re excited to incorporate Masimo W1 into our telehealth practices.”
    Masimo W1 for use in medical applications is pending FDA clearance in the U.S.

Qbtech, Global Leader in Objective ADHD Testing, Opening U.S. Headquarters in Houston

Retrieved on: 
Wednesday, May 3, 2023
Mental Health, Other Health, Health, Pharmaceutical, Telemedicine, Virtual Medicine, History of the National Health Service (England), National Health Service, Marketing, ADHD, Commercial director, Synthetic control method, Patient, Engineering, Growth, Diagnosis, FDA, Dietary supplement

Qbtech , the global leader in objective ADHD testing, today announces the opening of its new U.S. headquarters in Houston, Texas.

Key Points: 
  • Qbtech , the global leader in objective ADHD testing, today announces the opening of its new U.S. headquarters in Houston, Texas.
  • Qbtech is the market leader in objective measurement of ADHD symptoms, transforming ADHD care for individuals and society at large.
  • In addition to expanding on Qbtech’s mission for improved ADHD care, the Houston office also will support the local community.
  • “Houston was a natural choice for our U.S. headquarters, given its growing community of technical expertise and talent,” adds Doyle.

Dexcom rtCGM is Likely to be Cost-Saving, Study Suggests

Retrieved on: 
Wednesday, May 3, 2023
Health, Medical Devices, Diabetes, Health Technology, General Health, Clinical Trials, Pharmaceutical, CGM, Hypoglycemia, Blood, Probability, National Health Service, Type 2 diabetes, IQVIA, Life imprisonment, Fear, Quality of life, Hyperglycemia, Multimedia, Research, Quality-adjusted life year, QALY, Risk, DXCM, Patient, NHS, Engineered wood, Pharmaceutical industry, Dexcom, Glycated hemoglobin

The analysis suggests that, compared to finger pricks, use of rtCGM results in significant improvements in baseline glycated haemoglobin (HbA1c), as well as reductions in long-term diabetes-related complications and emergency department visits1.

Key Points: 
  • The analysis suggests that, compared to finger pricks, use of rtCGM results in significant improvements in baseline glycated haemoglobin (HbA1c), as well as reductions in long-term diabetes-related complications and emergency department visits1.
  • The cost-effectiveness of Dexcom rtCGM was sensitive to capture the quality of benefits associated with reduced fear of hypoglycaemia and avoidance of testing with finger pricks, as well as the HbA1c benefit associated with rtCGM use1.
  • Patients using rtCGM were assumed to have a 0.56% reduction in HbA1c based on the mean difference between groups after 12 months of follow-up.
  • Reduced fingerstick testing when using rtCGM was associated with a quality of life (QoL) benefit.